Targeting the ERβ/Angiopoietin-2/Tie-2 signaling-mediated angiogenesis with the FDA-approved anti-estrogen Faslodex to increase the Sunitinib sensitivity in RCC

Sunitinib has been used as the main therapy to treat the metastatic clear cell renal cell carcinoma (ccRCC) as it could function via suppressing the tumor growth and angiogenesis. Yet most ccRCC tumors may still regrow due to the development of sunitinib-resistance, and detailed mechanisms remain to...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Junfei, Zhang, Yong, Han, Zhenwei, Gao, Lei, Cui, Jinfeng, Sun, Yin, Niu, Yuanjie, You, Bosen, Huang, Chi-Ping, Chang, Chawnshang, Wang, Xiaolu, Yeh, Shuyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224303/
https://www.ncbi.nlm.nih.gov/pubmed/32409702
http://dx.doi.org/10.1038/s41419-020-2486-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224303/
https://www.ncbi.nlm.nih.gov/pubmed/32409702
http://dx.doi.org/10.1038/s41419-020-2486-0

Ejemplares similares